Joincare Pharmaceutical Group Industry Co (FRA:F9L) Marketable Securities: €131 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:F9L Joincare Pharmaceutical Group Industry Co Ltd FRA:F9L
80 GF Score
Price €6.60
GF Value €7.53
! 3 Warning Signs
View Full Analysis

What is Joincare Pharmaceutical Group Industry Co Marketable Securities?

Joincare Pharmaceutical Group Industry Co FRA:F9L 80 Marketable Securities is €131 Mil as of Mar. 2026. GuruFocus rates FRA:F9L with a GF Score™ of 80/100 and a GF Value™ of €7.53. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Joincare Pharmaceutical Group Industry Co's Marketable Securities for the quarter that ended in Mar. 2026 was €131 Mil.

Joincare Pharmaceutical Group Industry Co's annual Marketable Securities increased from Dec. 2023 (€11 Mil) to Dec. 2024 (€12 Mil) and increased from Dec. 2024 (€12 Mil) to Dec. 2025 (€205 Mil).

Joincare Pharmaceutical Group Industry Co  (FRA:F9L) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Joincare Pharmaceutical Group Industry Co Marketable Securities Related Terms

Joincare Pharmaceutical Group Industry Co Marketable Securities Historical Data

* Premium members only.

The historical data trend for Joincare Pharmaceutical Group Industry Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Joincare Pharmaceutical Group Industry Co Marketable Securities Chart

Joincare Pharmaceutical Group Industry Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.66 14.76 10.65 11.72 205.41

Joincare Pharmaceutical Group Industry Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.72 59.24 144.22 205.41 131.23
FRA:F9L
80GF Score
Joincare Pharmaceutical Group Industry Co Ltd FRA:F9L
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Joincare Pharmaceutical Group Industry Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €131 Mil mean?
Joincare Pharmaceutical Group Industry Co (FRA:F9L) has a Marketable Securities of €131 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Joincare Pharmaceutical Group Industry Co and its competitors.
Is Joincare Pharmaceutical Group Industry Co's Marketable Securities too high?
Joincare Pharmaceutical Group Industry Co's current Marketable Securities is €131 Mil. Overall, Joincare Pharmaceutical Group Industry Co has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Joincare Pharmaceutical Group Industry Co's Marketable Securities compare to ZTS?
Joincare Pharmaceutical Group Industry Co's Marketable Securities of €131 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Joincare Pharmaceutical Group Industry Co and its competitors. Joincare Pharmaceutical Group Industry Co's current Marketable Securities is €131 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joincare Pharmaceutical Group Industry Co stock overvalued right now?
Joincare Pharmaceutical Group Industry Co (FRA:F9L) has a current Marketable Securities of €131 Mil. The stock's GF Value™ is €7.53, compared to a current price of €6.60 — trading 12.4% below its estimated fair value. The current Marketable Securities is €131 Mil. Joincare Pharmaceutical Group Industry Co's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Joincare Pharmaceutical Group Industry Co (FRA:F9L), the current Marketable Securities is €131 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Joincare Pharmaceutical Group Industry Co (FRA:F9L) Overvalued in 2026?

Based on GuruFocus' analysis, Joincare Pharmaceutical Group Industry Co stock appears to be undervalued. The current stock price of €6.60 is trading 12.4% below its estimated GF Value™ of €7.53.

Key valuation signals for FRA:F9L:

  • Marketable Securities: €131 Mil
  • GF Value™: €7.53 vs. price of €6.60 (12.4% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the FRA:F9L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Joincare Pharmaceutical Group Industry Co Business Description

Other Exchanges 600380:China
Address No. 17, Langshan Road, North District, High-tech Zone, Nanshan District, Guangdong, Shenzhen, CHN, 518057
Joincare Pharmaceutical Group Industry Co Ltd is an integrated pharmaceutical company, the business scope covers healthcare products, APIs, final dosage forms, prescription drugs, OTCs, Chinese traditional medicine, chemical drugs, and testing agents. APIs are antibiotic series and their intermediates 7ACA, 4AA and F9. Prescription drugs focus on the realms of the digestive tract, a blood vessel of heart and brain, infection, tumor, nervous cerebrovascular section, urinary system etc. OTCs include gastrointestinal drug Dele-Livzon, Live Bifidobacterium Preparation, oral ulcer drugs Yiketie, cold medicine Antiviral Oral Granule, External use skin medicine.
80GF Score

Get the complete analysis for FRA:F9L

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.60
Price
€7.53
GF Value